Multi-center, Randomized, Double-blinded Assessment of TERIFLUNOMIDE (Aubagio®) in Extending the Time to the First Attack in Radiologically Isolated Syndrome: Baseline Characteristics of the TERIS Study. (P5-4.011)
Makaleler > Tam Makale · 2022
Yazarlar: Christine Lebrun Frenay, Cassandre Landes-Château, Aksel Siva, Maria Pia Sormani, Lydiane Mondot, Patrick Vermersch, Anne Caroline Papeix, Eric Thouvenot, Pierre Labauge, Francoise Durand Dubief, Husnu Efendi, Emmanuelle Le Page, Murat Terzi, Nathalie Derache, Bertrand Bourre, Robert Hoepner, Rana Karabudak, Jerome De Seze, Jonathan Ciron, Pierre Clavelou, Sandrine Wiertlewski, Omer Turan, Ayşe Nur YÜCEYAR, Mikael Cohen, Orhun Kantarci, Daniel Pelletier, Darin Okuda
Neurology, Uluslararası, Wos, 2022, cilt 98
DOI: 10.1212/wnl.98.18_supplement.1116
Özet
This study aims to analyze the efficacy of teriflunomide (Aubagio®) in extending the time to a seminal acute or progressive demyelinating event in a cohort of Radiologically isolated syndrome (RIS) subjects within Europe and Turkey.